agencies and payer representatives should be obtained. In addition, funding support from the EU and industry should be obtained.
Call 1: increase awareness in the European community about the burden MS places on patients, caregivers and society
There is limited awareness and understanding within society and with policy and decision makers that even MS patients who are mildly to moderately disabled, that is, have an Expanded Disability Status Scale (EDSS) of 3, experience similar or even worse health-related quality of life (QoL) than patients with chronic ischaemic heart disease (IHD) or noninsulin-dependent diabetes mellitus (NIDDM). 9 Moreover, whereas IHD and NIDDM usually affect older people, MS is a disease of young people which peaks around the age of 30 years when they are at the top of their productive life. 9 Therefore, MS may have a greater negative impact on productivity loss and unemployment rate than IHD or NIDDM. Moreover, as MS progresses, patients become increasingly dependent of their family, who may also have to take a part-time job or stop work completely. 9 This should be realised when decisions on allocation of healthcare budgets to chronic diseases are taken. Therefore, European citizens as well as policy and decision makers should be (better) educated on the fact that MS has a major impact on the life of young people and their families and that related loss of work/productivity and unemployment pose (in comparison with other chronic diseases) a substantial (cost) burden on society. The development of policies addressing appropriate funding for home adaptations, rehabilitation therapy and providing financial incentives for employers in order to get or keep MS patients at work can be seen as a result of this call.
Call 2: improve communication towards the European community on the direct and indirect cost burden of MS
Direct costs related to, for example, hospital and outpatient care and drug treatment costs are easier to estimate than indirect costs related to loss of productivity, unemployment and/or disability pensions. 9 However, in most chronic diseases, indirect costs represent about 50% of total healthcare costs and, in MS, indirect costs also increase with increasing disability. 9 Therefore, when evaluating the impact of MS treatment on healthcare budgets, this should not only include direct drug costs but also the potential impact of the treatment on disability progression and, consequently, indirect costs. 9 With the introduction of several new disease-modifying drugs (DMDs) over the last years, the urgent need for a large, pan-European cost-of-illness study/model adequately evaluating not only direct (drug) costs but also indirect costs related to MS management was identified at the first Colloquium. 5, 9 It was discussed at the second Colloquium that this call has been taken up by the EMSP who is currently overseeing the execution of such a study in around 16 European countries involving thousands of patients. 9 Additional support/funding by the European Commission (EC) may still be required. Moreover, when during HTA the long-term cost-effectiveness of MS treatment is assessed and payers subsequently decide on access to treatment, it should be factored in that treatments which reduce disability progression (as recently demonstrated for interferon-β (INF) and glatiramer acetate (GA)) will keep patients with MS and their caregivers longer at work. As such they will reduce indirect costs and, therefore, very likely also total healthcare costs. Health authorities should focus as well on total healthcare costs instead of the individual budgets of different stakeholders/ministries.
Call 3: perform patient research to (re)define treatment goals/endpoints from a humanistic/ patient perspective point of view
In the current marketing authorisation, HTA and reimbursement decisions emphasis is still placed on shortterm endpoints, that is, the reduction of the duration, severity and sequelae of relapses. 8 Nevertheless, they recognise that the main benefit of DMDs or treatment lies in their ability to delay the progression to an EDSS of 6 (when walking aids are required to remain mobile). Moreover, there is research suggesting that patients prefer to delay disability progression and prevent serious adverse events over decreasing relapse rate. 6, 9 Therefore, the EU should invest more in research evaluating what patients ultimately expect from treatment in order to re-establish the endpoints for treatment outcome in clinical trials and improve the decision-making on access to treatment during HTA and reimbursement discussions.
Call 4: develop new tools to better capture the total clinical burden of MS
In addition to reducing time to relapse and/or relapse rate, preventing or delaying progression of disability and keeping patients as long as possible mobile is a major objective in the management of MS, both from a patient 6 and a regulator/EMA point of view. 8 Although the EDSS is still the recommended tool by authorities such as EMA to capture disability progression in clinical trials performed to obtain marketing authorisation and it represents a robust outcome for health economists, it is realised that it has several limitations. 8 Therefore, they encourage researchers and clinicians to develop and validate new tools for capturing disability in a broader sense than just mobility/walking ability. 8 In addition, researchers and clinicians should develop and validate with priority instruments that better capture patients' expectations from MS treatment and which can be self-administered and completed by the patient. 8 This includes bothersome, albeit often hidden, MS symptoms for society such as fatigue and cognitive decline, due to which patients may often refrain from education and/or work. 8 The EU should be aware of the importance of funding research focused at developing these new tools.
Call 5: develop a protocol for standardisation of magnetic resonance imaging for optimising its use as a marker of disability progression in MS
Magnetic resonance imaging (MRI) is, in addition to some clinical markers, still the most important biomarker for diagnosis, detection of disease activity, monitoring and predicting disease evolution and predicting (long-term) response to treatment in patients with relapsing MS. 6 Because of their clinical value as a proxy for disability progression, assessment of brain atrophy, lesion volume and cortical lesions should move to the next step, that is, integration in multicentre clinical trials and the clinical routine. 6 However, important issues hampering implementation of these and MRI variables in general are the lack of standardised MRI protocols among hospital and private practices as well as the heterogeneity in hardware throughout Europe (a 3-T scanner detects about 30% more lesions than a scanner with 1.5 T field strength). 6 Therefore, it was indicated at the first Colloquium that researchers and neuroradiologists should urgently develop a protocol for standardisation of measuring MRI variables including brain atrophy in multi-centre clinical trials and clinical practice. 6 The second Colloquium preparatory working group on imaging biomarkers/MRI proposed the standardised MRI acquisition protocol as shown in Table 1 , 6 which is largely in line with a recent protocol published by MAGNIMS. 10 It was also indicated that European and national MS and neurologist societies can play an important role in the implementation of this protocol by supporting its use in clinical practice. Moreover, it was considered crucial to use the same standardised protocol as well as the same MRI machine in one patient during follow-up/over time. 6 In addition, there is need for fully automated pipelines for measuring and analysing MRI outcomes, which should be integrated in all major MRI vendors' post-processing software and allow transfer of information into a picture archiving and communication system (PACS). 6 Also the reports of MRI results from radiologists to neurologists should be standardised and combined with the conventional (written) report. 6 Certification of centres and (neuro)radiologists fulfilling minimum technical/MRI machine requirements who have adequate quality control programmes and standardised protocols in place by ECTRIMS or ESNR may help to accelerate standardisation. 6 However, in the end successful implementation of routine MRI evaluations into clinical practice will very likely only occur if payers and health authorities are convinced of its value and will therefore reimburse it.
Call 6: support research to find other (molecular) biomarkers which can predict long-term disability progression and (monitor) individual treatment response
Apart from MRI biomarkers, several molecular biomarkers have been evaluated for diagnosing MS, predicting conversion from clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (CDMS) and predicting and monitoring disability progression and treatment response. 6 The second Colloquium preparatory working group on molecular biomarkers identified the presence of IgG oligoclonal bands (OCB) and an elevated IgG index as well as (albeit to a lesser extent) Chitinase 3-like 1 (CHI3L1) in the cerebrospinal fluid (CSF) and vitamin D in blood as the best candidates to further validate for predicting conversion from CIS to CDMS and more rapid disability progression. 6 Neurofilaments (NFs), light and heavy chain in the CSF and light chain in blood, were considered to be among the most promising ones for predicting disability progression in CDMS/ relapsing-remitting multiple sclerosis (RRMS). 6 CSF OCB IgM, multimodal evoked potentials and optical coherence tomography may be other interesting biomarkers to further investigate in this regard. 6 Pharmacogenomics studies may identify genetic variants predicting response to DMDs. 6 When this will result in giving the right treatment to the right patient at the right time considerable improvements in the quality of care and cost-savings can be made. Therefore, the EU should increase funding allowing further development and validation of functional and structural biomarkers including molecular biomarkers such as CHI3L1 and NFs. Validation of promising body fluid biomarkers can probably benefit from existing European consortia engaged in CSF and/or serum biomarker research that have already built-up large biobanks. Table 1 . Proposal second Colloquium MRI working group for standardised brain MRI acquisition protocol for an optimised follow-up of MS patients.
Follow-up examinations
• Mandatory sequences • Axial proton density or T2-FLAIR/T2-weighted • Highly recommended sequence
• 2D or 3D contrast-enhanced T1-weighted • Optional sequences
• Unenhanced high-resolution isotropic 3D T1weighted • 2D and/or 3D dual inversion recovery (DIR) • Axial diffusion-weighted imaging FLAIR: fluid-attenuated inversion recovery.
Call 7: align CHMP/EMA and HTA decisionmaking process
Although marketing authorisation is centrally arranged in Europe by the CHMP/EMA, the HTA decision process is still performed at a member state/ national level. Moreover, as the HTA process is largely driven by the (long-term) cost-effectiveness of new treatment and it will take some time before the results of the large, cross-European cost-of-illness study/model (which includes all recently introduced treatments) will be available, this can lead to different decisions on treatment access in the European countries. 9 The EC is funding since 2010 a more closely working together of the CHMP/EMA and the European Network for HTA (EUnetHTA). 9 Nevertheless, the marketing authorisation process and HTA process are not fully aligned yet and, influenced by national economy and political considerations, this can still result in delayed access and/or inequalities in access across Europe. Therefore, the EU/EC should continue to put efforts in engaging early cooperation between pharmaceutical industries, the EMA and HTAs to prospectively identify key evidence needs for the regulatory and reimbursement processes in order to ensure rapid access of effective and safe treatment providing value for money for all people living with MS in the EU. Moreover, in order to ensure that patients' expectations from treatment are factored in in the decisions taken, patient organisations such as EMSP should be involved in these policy revisions.
Additionally, the recent marketing authorisation of alemtuzumab has learned that the marketing authorisation decision-making process by the EMA/CHMP should become consistent for different treatments evaluated. 8 Attempts of the regulators such as the 'adaptive licensing approach', which gives faster but conditional initial marketing authorisation and accelerate quick access to new treatment, are also highly encouraged. 8
Call 8: develop separate EMA guidelines for evaluating follow-on products of non-biological complex drugs
The upcoming expiry of patents of first-line DMDs such as INF and GA holds the potential that cheaper follow-on products will increase access to treatment for MS patients living across Europe. However, patients and HCPs should be reassured by the regulators and governments/Ministries of Health that the guidelines required to demonstrate 'similarity' will ensure that the developed follow-on products are indeed as effective and safe (in the long term) as their originator products. Although there exist in MS separate guidelines for generics (e.g. corticosteroid) and biosimilars (e.g. INF-β), there are today no sufficiently defined guidelines for non-biological complex drugs (NBCDs; for example, GA). 8 The examples described in the review paper in this supplement by Crommelin et al. 8 show that there can be important differences in gene-expression profiles, long-term pre-clinical toxicology/mortality data or even clinical efficacy and safety between NBCDs and their follow-on products. These show that regulators should prioritise the development of separate clearly defined guidelines for demonstrating similarity of follow-on NBCDs in order to ensure continuous safety and efficacy of first-line treatment for people living with MS. As with biosimilar products, NBCDs are inexorably linked to their production process; therefore, similarity cannot be assumed for their follow-on product(s). An extensive analytical characterisation of a follow-on product complemented with a clinical trial programme (with clear instructions on the design) seems to be needed to ascertain safe use in clinical practice.
Call 9: support people with MS remaining (physically) active and at work and stimulate the implementation of specialised care centres
For the QoL of people living with MS, it is important to remain as long as possible mobile and out of a wheelchair. In this way, they can stay as long as possible independent from a caregiver and can continue to work and socialise/participate in society. Family members can continue to live their own life and perform their own job. This all will reduce the cost burden on society.
Although rehabilitation research is not always welldesigned, usually underpowered and lacks uniform outcome measures, it has been shown that when people with MS remain physically active/are involved in exercise therapy, this stimulates their muscle function and will keep them involved in mobility-related activities of daily living (ADL). 7 In addition, they continue with socialising, which has a positive impact on their mood/mental QoL. Therefore, people living with MS should be stimulated and supported with exerciserelated activities as this may reduce indirect costs and improve their mental health. At the second Colloquium, the working group for multi-disciplinary care and patient activation defined patient activation not only as 'Structured exercise to improve activity' but also as 'Behavioural lifestyle change to improve participation (in physical activity)'. 7 This should be supported because it seems that MS patients have less physical activity than healthy controls. 11 This working group also recommended to perform well-designed and powered phase III studies to increase the evidence on the impact of exercise/physical activity on outcomes such as walking, fatigue, ADL and QoL. 7 In addition to improved access to (MS specialised) rehabilitation therapists to support physical activity, also improved access to other disciplines within the healthcare sector such as MS specialised nurses and networks of different specialists aware of the specificities of MS care (such as psychologists, urologists and social workers) will increase the quality of care. This can be realised in reference centres with an MDT consisting of minimally a neurologist, MS nurse, rehabilitation physician and psychologist. 7 Moreover, the availability of innovative treatments characterised by a high complex safety profile requires quick consultation with valid specialists, such as cardiologists, infectologists and ophthalmologists, which is possible only in well-organised (reference) centres. However, whereas references centres exist in some countries, they are absent in most member states. At the second Colloquium, there was also discussion as to who should coordinate the care. Should this be the neurologist or (due to time and resource constraints) the MS nurse? 7 The tendency to put the patient in the middle as self-management of chronic diseases by patients and eHealth such as 'patientslikeme' (https://www.patientslikeme.com/) and 'Health Vault' (https://www.healthvault.com/be/ en) but also (free) apps on smartphones for tracking symptoms and physical activity are encouraged more and more was noticed as an important change for future patient care. Probably, the best care model is the concordance model in which patient and HCPs work as partners. 7 In this regard, it should be noticed that also in an information technology (IT)-based environment not all patients (and/or caregivers) are capable to do so. Finally, the healthcare system may perhaps better move from sickness-behaviour to health/wellness behaviour focussed.
Call 10: support the continuation of multistakeholder colloquia
The evaluation of the participants of the first MS Multi-stakeholder Colloquium indicated a high level of commitment to continue our initiative. However, it was also mentioned that far more active involvement in the programme development from EMSP, ECTRIMS, ECF, MAGNIMS, RIMS, MS nurse representatives, CHMP, HTA bodies and payer representatives should be achieved and preparatory group workshops should precede the colloquium discussing the solution propositions for improving the life of MS patients in Europe. At the second Colloquium, RIMS and MS nurse representatives were involved to address together with other HCPs Call to Action 9 from the first Colloquium. Other working groups made progress with regard to development of guidance propositions/recommendations for several other Calls to Actions as discussed in this document. Currently, potential collaboration with the ECF for a third Colloquium in 2017 is being elaborated.
